Biogen Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Biogen Inc 公司

Biogen Inc. 是一家全球性生物制药公司。该公司致力于为全球患有严重和复杂疾病的人们发现、开发和提供先进的治疗方法。该公司经营一系列药物，用于治疗多发性硬化症 (MS)、脊髓性肌萎缩症 (SMA)、阿尔茨海默病和肌萎缩侧索硬化症 (ALS)。该公司专注于推进其在神经病学、专业免疫学和罕见疾病领域的产品线。其上市产品包括用于治疗 MS 的 TECFIDERA、VUMERITY、AVONEX、PLEGRIDY、TYSABRI 和 FAMPYRA；用于治疗 SMA 的 SPINRAZA；用于治疗弗里德赖希共济失调的 SKYCLARYS；用于治疗 ALS 的 QALSODY 和用于治疗严重斑块状银屑病的 FUMADERM。它还与 Eisai 合作，将 LEQEMBI 商业化，用于治疗阿尔茨海默病，并与 Sage 合作，将 ZURZUVAE 商业化，用于治疗产后抑郁症 (PPD)。

Biogen Inc简介



公司代码BIIB

公司名称Biogen Inc

上市日期Sep 17, 1991

CEOMr. Christopher A. (Chris) Viehbacher

员工数量7605

证券类型Ordinary Share

年结日Sep 17

公司地址225 Binney Street

城市CAMBRIDGE

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编02142

电话17814642000

网址https://www.biogen.com/

公司代码BIIB

上市日期Sep 17, 1991

CEOMr. Christopher A. (Chris) Viehbacher

Biogen Inc公司高管



名称

名称/职务

职务

持股

持股变动

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

56.35K

+55.38%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

29.22K

+12.13%

Dr. Ginger Gregory, Ph.D.

Chief Human Resources Officer, Executive Vice President

17.50K

+28.86%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

14.22K

+1.19%

Dr. Stephen A. Sherwin, M.D.

Independent Director

12.35K

+23.75%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

11.23K

-16.53%

Mr. Jesus B. Mantas

Independent Director

8.42K

+39.19%

Ms. Priya Singhal, M.D.

Executive Vice President, Head of Development

5.77K

-8.22%

Dr. Maria C. Freire, Ph.D.

Independent Director

5.47K

+76.33%

Ms. Susan Langer

Independent Director

3.79K

+166.90%

名称

名称/职务

职务

持股

持股变动

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

56.35K

+55.38%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

29.22K

+12.13%

Dr. Ginger Gregory, Ph.D.

Chief Human Resources Officer, Executive Vice President

17.50K

+28.86%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

14.22K

+1.19%

Dr. Stephen A. Sherwin, M.D.

Independent Director

12.35K

+23.75%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

11.23K

-16.53%

收入明细

单位: USD更新时间: 10月6日周一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

MS product revenues-TYSABRI

839.80M

31.74%

Spinal Muscular Atrophy-SPINRAZA

543.00M

20.53%

MS product revenues-Fumarate

405.90M

15.34%

MS product revenues-Interferon

246.70M

9.33%

Biosimilar product revenues-BENEPALI

112.10M

4.24%

其他

498.00M

18.82%

地区USD

名称

营收

占比

United States

1.38B

52.21%

Rest of World

937.60M

35.44%

United states-Revenues from anti-CD20 therapeutic

467.30M

17.66%

Rest of World-Other revenues

244.60M

9.25%

业务

地区

业务USD

名称

营收

占比

MS product revenues-TYSABRI

839.80M

31.74%

Spinal Muscular Atrophy-SPINRAZA

543.00M

20.53%

MS product revenues-Fumarate

405.90M

15.34%

MS product revenues-Interferon

246.70M

9.33%

Biosimilar product revenues-BENEPALI

112.10M

4.24%

其他

498.00M

18.82%

股东统计

更新时间: 8月19日周二

持股股东

股东类型

持股股东

占比

The Vanguard Group, Inc.

11.74%

PRIMECAP Management Company

10.78%

BlackRock Institutional Trust Company, N.A.

5.59%

State Street Global Advisors (US)

5.09%

Wellington Management Company, LLP

3.27%

其他

63.53%

持股股东

占比

The Vanguard Group, Inc.

11.74%

PRIMECAP Management Company

10.78%

BlackRock Institutional Trust Company, N.A.

5.59%

State Street Global Advisors (US)

5.09%

Wellington Management Company, LLP

3.27%

其他

63.53%

股东类型

持股股东

占比

Investment Advisor

51.55%

Investment Advisor/Hedge Fund

24.28%

Hedge Fund

8.68%

Pension Fund

2.62%

Research Firm

2.27%

Sovereign Wealth Fund

1.59%

Bank and Trust

1.38%

Individual Investor

0.17%

Venture Capital

0.14%

其他

7.32%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

1987

135.68M

92.54%

-8.70M

2025Q2

2075

135.74M

92.58%

-12.69M

2025Q1

2149

136.82M

93.38%

-11.44M

2024Q4

2130

138.58M

94.69%

-5.19M

2024Q3

2109

135.95M

93.33%

-6.54M

2024Q2

2116

135.72M

93.21%

-7.14M

2024Q1

2121

136.44M

93.87%

-5.95M

2023Q4

2151

135.61M

93.59%

-2.07M

2023Q3

2177

132.42M

91.43%

-7.53M

2023Q2

2240

133.77M

92.42%

-4.86M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

17.21M

11.74%

+255.44K

+1.51%

Jun 30, 2025

PRIMECAP Management Company

15.80M

10.78%

-141.14K

-0.89%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

8.19M

5.59%

-504.36K

-5.80%

Jun 30, 2025

State Street Global Advisors (US)

7.47M

5.09%

+71.90K

+0.97%

Jun 30, 2025

Wellington Management Company, LLP

4.80M

3.27%

+125.98K

+2.70%

Jun 30, 2025

Geode Capital Management, L.L.C.

3.92M

2.67%

+71.29K

+1.85%

Jun 30, 2025

Point72 Asset Management, L.P.

3.83M

2.61%

+3.42M

+840.86%

Jun 30, 2025

Invesco Capital Management (QQQ Trust)

3.00M

2.05%

-10.62K

-0.35%

Aug 31, 2025

Norges Bank Investment Management (NBIM)

2.26M

1.54%

-61.02K

-2.62%

Jun 30, 2025

Invesco Capital Management LLC

2.04M

1.39%

+32.06K

+1.59%

Jun 30, 2025

持股ETF



更新时间: 10月6日周一

机构名称

占比

iShares Neuroscience and Healthcare ETF

3.81%

First Trust NASDAQ Pharmaceuticals ETF

3.54%

VanEck Biotech ETF

3.36%

First Trust NYSE Arca Biotechnology Index Fund

3.19%

Invesco Pharmaceuticals ETF

2.45%

SPDR S&P Biotech ETF

2.31%

First Trust Health Care Alphadex Fund

2.26%

Invesco Nasdaq Biotechnology ETF

1.98%

ProShares Ultra Nasdaq Biotechnology

1.97%

iShares Health Innovation Active ETF

1.96%

iShares Neuroscience and Healthcare ETF

占比3.81%

First Trust NASDAQ Pharmaceuticals ETF

占比3.54%

VanEck Biotech ETF

占比3.36%

First Trust NYSE Arca Biotechnology Index Fund

占比3.19%

Invesco Pharmaceuticals ETF

占比2.45%

SPDR S&P Biotech ETF

占比2.31%

First Trust Health Care Alphadex Fund

占比2.26%

Invesco Nasdaq Biotechnology ETF

占比1.98%

ProShares Ultra Nasdaq Biotechnology

占比1.97%

iShares Health Innovation Active ETF

占比1.96%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据